Herzuma® (CT-P6) is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018.
Herzuma® is a humanized monoclonal antibody that is designed to bind selectively to the extracellular domain of an antigen called human epidermal growth factor receptor 2 (HER2).
Herzuma® is indicated for the treatment of adult patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Herzuma®, biosimilar trastuzumab (approved by the EMA in 2018)
- Early breast cancer
- Metastatic breast cancer
- Metastatic gastric cancer
Protein Type :
- Monoclonal antibody (mAb)
Mechanism of Action :
- Trastuzumab prevents auto-activation of HER2 receptor, activates antibody-dependent cellular cytotoxicity, and promotes degradation of HER2.